Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
- 已启动随机第二阶段研究，评估casdozokitug、toripalimab和阿伐西普联合用于肝癌患者的效果 -
REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a poster presentation at the upcoming 2025 ASCO GI Annual Meeting, being held January 23-25, 2025, in San Fransisco, CA.
加州红木城市，2024年12月18日（全球新闻通讯）-- Coherus BioSciences, Inc.（（"Coherus, 纳斯达克:CHRS）今天宣布，突显其第二阶段临床试验最终临床及生物标志物数据的摘要，评估选择性且强效的IL-27拮抗抗体casdozokitug（casdozo）与阿特珠单抗（atezo）和阿伐西普（bev）联合用于未接受过治疗的、不可切除的局部晚期或转移性肝细胞癌患者（HCC），已被选择在即将于2025年1月23日至25日在加州旧金山举行的2025年ASCO GI年会上进行海报展示。
